What is Regenxbio's deferred revenue, net of current portion?

Regenxbio (RGNX) reported deferred revenue, net of current portion of $22.78M in Q1 2026.

How has Regenxbio's deferred revenue, net of current portion changed year-over-year?

Regenxbio's deferred revenue, net of current portion decreased by 13.4% year-over-year, from $26.3M to $22.78M.

Regenxbio RGNX Deferred revenue, net of current portion

Deferred revenue, net of current portion at other companies

Regeneron PharmaceuticalsREGN

$225.1M+6.3%

Sarepta Therapeutics, Inc.SRPT

——

4D Molecular TherapeuticsFDMT

——

Sutro BiopharmaSTRO

——

Arrowhead ResearchARWR

——

Other financials

Income statement

See full

Revenue$6.4M-92.8%

Gross profit$14.9M+35.7%

Operating income-$83.4M-787%

Net income-$90.1M-1,580%

EPS (diluted)-$1.72-1,533%

Balance sheet

See full

Cash & equivalents$15.2M-88.3%

Total debt$71.1M-11.0%

Total equity$21.1M-92.3%

Total assets$341.9M-30.4%

Cash flow

See full

Operating cash flow-$76.2M-327%

CapEx$1.2M+20.6%

Free cash flow-$77.4M-337%

Valuation

See full

Market cap$529.38M+24.6%

Enterprise value$585.22M+56.3%

P/S6×+3.3×

Profitability

See full

Gross margin59.7%+1.0pp

Operating margin-292.3%-613pp

Net margin-330.2%-588pp

FCF margin-269.2%-364pp

Returns & leverage

See full

Return on equity-196.4%-288pp

Debt / equity3.4×+3.1×

Current ratio2.6×-0.3×

Where this comes from

Reported directly by Regenxbio in its filing.

Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityNoncurrent.

The official record: Regenxbio’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Regenxbio's deferred revenue, net of current portion.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Regenxbio's deferred revenue, net of current portion?: Regenxbio (RGNX) reported deferred revenue, net of current portion of $22.78M in Q1 2026.
How has Regenxbio's deferred revenue, net of current portion changed year-over-year?: Regenxbio's deferred revenue, net of current portion decreased by 13.4% year-over-year, from $26.3M to $22.78M.